About: Abacavir

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Abacavir Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. [Wikipedia] Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B59FD-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B59FE-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B59FF-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5A00-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr. 2007 May 1;45(1):1-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17356469 # FDA label # http://pharmgkb.org/pathway/PA166104634# (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	1.54 ± 0.63 hours (en)
http://linked.open...ugbank/indication	For the treatment of HIV-1 infection, in combination with other antiretroviral agents. (en)
sameAs	Abacavir Abacavir
Title	Abacavir (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/chebi/2360 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/chemspider/58649 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/drugbank/DB01048 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/kegg-compound/C07624 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/kegg-drug/D07057 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/national-drug-code-directory/0173-0661-01 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/pharmgkb/PA448004 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/pubchem-compound/441300 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/pubchem-substance/46505718 http://linked.opendata.cz/resource/drugbank/drug/DB01048/identifier/wikipedia/Abacavir
http://linked.open...mechanismOfAction	Abacavir is a carbocyclic synthetic nucleoside analogue and an antiviral agent. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Viral DNA growth is terminated because the incorporated nucleotide lacks a 3'-OH group, which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation. (en)
http://linked.open...drugbank/packager	A-S Medication Solutions LLC Baxter International Inc. Alphapharm Party Ltd. A-S Medication Solutions LLC Bryant Ranch Prepack Corepharma LLC Innovative Manufacturing and Distribution Services Inc. Dispensing Solutions Diversified Healthcare Services Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/1340589 http://linked.opendata.cz/resource/drugbank/patent/2216634 http://linked.opendata.cz/resource/drugbank/patent/2289753 http://linked.opendata.cz/resource/drugbank/patent/5089500 http://linked.opendata.cz/resource/drugbank/patent/6641843
http://linked.open...outeOfElimination	Elimination of abacavir was quantified in a mass balance study following administration of a 600-mg dose of 14C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose. Renal excretion of unchanged abacavir is a minor route of elimination in humans. (en)
http://linked.open.../drugbank/synonym	Abacavir (en) ABC (en) {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol (en)
http://linked.open...drugbank/toxicity	Some myocardial degeneration has been noticed in rats and mice. The most commonly reported adverse reactions of at least moderate intensity (incidence ≥10%) in adult HIV-1 clinical trials were nausea, headache, malaise and fatigue, nausea and vomiting, and dreams/sleep disorders. Serious hypersensitivity reactions have been associated with abacavir which has been strongly linked to the presence of the HLA-B*57:01 allele. This reaction manifests itself in patients within the first 6 weeks of treatment. Patients should be tested for the presence of this allele as recommended by the U.S Food and Drug Administration (FDA). (en)
http://linked.open...umeOfDistribution	* 0.86 ± 0.15 L/kg [IV administration] (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/08-18-08-20
http://linked.open...k/foodInteraction	Avoid alcohol. (en) Take without regard to meals. (en) Abacavir is partly metabolised through the alcohol-dehydrogenase enzyme system. (en) Alcohol significantly increases abacavir's area under the curve (about 41%). (en)
http://linked.open.../drugbank/mixture	Epzicom Kivexa Trizivir
http://linked.open...nk/proteinBinding	Moderate (approximately 50%). Binding of abacavir to plasma protein was independent of concentration. (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	"DrugSyn.org":http://www.drugsyn.org/Abacavir.htm (en)
foaf:page	http://www.drugs.com/cdi/abacavir.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1527.shtml http://www.rxlist.com/cgi/generic/abavir.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5A05-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5A0B-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5A0A-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5A07-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5A08-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5A09-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5A1B-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5A03-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5A1D-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5A01-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5A04-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5A02-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Abacavir
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A11-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A12-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5A0C-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5A0D-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5A0F-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5A0E-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A10-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapid and extensive after oral administration (83% bioavailability, tablet). When a 300 mg tablet is given twice daily to subjects, the peak plasma concentration (Cmax) was 3.0 ± 0.89 mcg/mL and the area under the curve (AUC 0-12 hours) was 6.02 ± 1.73 mcg•hr/mL. (en)
http://linked.open.../affectedOrganism	Human Immunodeficiency Virus (en)
http://linked.open...casRegistryNumber	136470-78-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 0.80 ± 0.24 L/hr/kg [asymptomatic, HIV-1-infected adult patients receiving single (IV dose of 150 mg] (en)
http://linked.open...gbank/containedIn	Ziagen 300 mg tablet Epzicom tablet Ziagen 20 mg/ml Solution
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5A17-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5A19-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5A1A-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B5A1C-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5A16-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5A15-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5A18-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5A06-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5A13-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5A14-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software